NewcelX (NCEL) Non-Current Debt (2020 - 2022)
NewcelX (NCEL) posted quarterly Non-Current Debt of $354336.0 for Q2 2022, up 26.09% quarter-over-quarter from $281015.0 in Q4 2020.
NewcelX (NCEL) Non-Current Debt (2020 - 2022) Analysis & Trends
NewcelX (NCEL) has reported Non-Current Debt for 2 consecutive years, with $354336.0 the latest figure, recorded in Q2 2022.
- In Q2 2022, Non-Current Debt changed N/A year-over-year to $354336.0; the TTM figure through Jun 2022 stood at $354336.0 (changed N/A YoY), while the FY2020 annual figure was $281015.0, changed N/A from the prior year.
- Non-Current Debt improved to $354336.0 in Q2 2022 per NCEL's latest filing, from $281015.0 in the prior quarter.
- Across five years, Non-Current Debt topped out at $354336.0 in Q2 2022 and bottomed at $281015.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 8.96 Bn |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 354,336.00 |
| Dec 31, 2020 | 281,015.00 |